公开(公告)号：US20170029521A1

公开(公告)日：2017-02-02

申请号：US15197496

申请日：2016-06-29

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Tom VINK ,  Janine SCHUURMAN ,  Paul PARREN ,  Rob AALBERSE ,  Marijn VAN DER NEUT KOLFSCHOTEN

IPC: C07K16/28 ,  A61K51/10 ,  A61K47/48

Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

Abstract translation: 本发明涉及稳定的IgG4抗体，涉及产生此类抗体的方法以及此类抗体作为药物的用途。 在一个主要方面，本发明涉及一种稳定的IgG4抗体，其包含重链和轻链，其中所述重链包含具有在位置（409）处的Arg残基取代的人IgG4恒定区， 位置（405）或位置（370）处的Lys残基。

公开(公告)号：US20240209117A1

公开(公告)日：2024-06-27

申请号：US18507869

申请日：2023-11-13

Applicant: GENMAB A/S

Inventor： Aran Frank LABRIJN ,  Joyce I. MEESTERS ,  Edwald T. J. VAN DER BREMER ,  Joost J. NEIJSSEN ,  Patrick VAN BERKEL ,  Bart DE GOEIJ ,  Tom VINK ,  Jan VAN DE WINKEL ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/46 ,  A61K39/00 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/40 ,  G01N33/68

CPC classification number: C07K16/468 ,  C07K16/1063 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/40 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins

公开(公告)号：US20210061919A1

公开(公告)日：2021-03-04

申请号：US16947021

申请日：2020-07-15

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Tom VINK ,  Janine SCHUURMAN ,  Paul PARREN ,  Rob AALBERSE ,  Marijn VAN DER NEUT KOLFSCHOTEN

IPC: C07K16/28 ,  A61K51/10 ,  C07K16/00 ,  A61K47/68 ,  C07K16/16 ,  C07K16/18

Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

公开(公告)号：US20200262932A1

公开(公告)日：2020-08-20

申请号：US16777053

申请日：2020-01-30

Applicant: GENMAB A/S

Inventor： Aran Frank LABRIJN ,  Joyce I. MEESTERS ,  Ewald T. J. VAN DEN BREMER ,  Joost J. NEIJSSEN ,  Patrick VAN BERKEL ,  Bart DE GOEIJ ,  Tom VINK ,  Jan VAN DE WINKEL ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/46 ,  G01N33/68 ,  C07K16/40 ,  C07K16/32 ,  C07K16/28 ,  C07K16/10

Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins

公开(公告)号：US20180194845A1

公开(公告)日：2018-07-12

申请号：US15832366

申请日：2017-12-05

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD ,  Jan VAN DE WINKEL ,  David SATIJN ,  Paul PARREN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Edward N. VAN DEN BRINK

IPC: C07K16/28 ,  C07K16/32 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20180179286A1

公开(公告)日：2018-06-28

申请号：US15832421

申请日：2017-12-05

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD ,  Jan VAN DE WINKEL ,  David SATIJN ,  Paul PARREN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Edward N. VAN DEN BRINK

IPC: C07K16/28 ,  C07K16/32 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20170136130A1

公开(公告)日：2017-05-18

申请号：US15277626

申请日：2016-09-27

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: A61K39/00 ,  C07K16/36 ,  A61K45/06

CPC classification number: C07K16/30 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6849 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

公开(公告)号：US20160237161A1

公开(公告)日：2016-08-18

申请号：US14990869

申请日：2016-01-08

Applicant: GENMAB A/S

Inventor： Michel DE WEERS ,  Tim WALSETH ,  Jan VAN DE WINKEL ,  Tom VINK ,  Paul PARREN

IPC: C07K16/28 ,  A61K45/06 ,  G01N33/573 ,  A61K39/395

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/76 ,  G01N33/573 ,  G01N2333/91148

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US20160046727A1

公开(公告)日：2016-02-18

申请号：US14830336

申请日：2015-08-19

Applicant: GENMAB A/S

Inventor： Aran Frank LABRIJN ,  Joyce I. MEESTERS ,  Ewald T. J. VAN DEN BREMER ,  Joost J. NEIJSSEN ,  Patrick VAN BERKEL ,  Bart DE GOEIJ ,  Tom VINK ,  Jan VAN DE WINKEL ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/40 ,  G01N33/68 ,  C07K16/28

CPC classification number: C07K16/468 ,  A61K2039/505 ,  C07K16/1063 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6854

Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins

Abstract translation: 新型异二聚抗体-Fc的蛋白质，例如双特异性抗体，以及用于产生这种蛋白质的新方法

公开(公告)号：US20140348833A1

公开(公告)日：2014-11-27

申请号：US14199391

申请日：2014-03-06

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Paul PARREN ,  Willem Karel BLEEKER ,  Klaus EDVARDSEN ,  Jeroen Lammerts VAN BUEREN ,  Thomas VALERIUS ,  Michael DECHANT ,  Wencke WEISNER ,  Sven BERGER

IPC: C07K16/40 ,  G01N33/573 ,  C07K16/46

CPC classification number: C07K16/40 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/573

Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.

Abstract translation: 本发明涉及用于治疗肿瘤的新方法，包括施用双特异性抗体或两种或多种识别相同靶抗原或抗原复合物的非交叉阻断抗体的组合。 特别地，本发明涉及用于诱导补体介导的细胞杀伤治疗肿瘤的方法，所述方法包括向有需要的人共同施用第一抗体和第二抗体，其中所述第一抗体 结合EGFR，所述第二抗体结合EGFR，所述第一和第二抗体是非交叉阻断的，并且所述给药方案使得在肿瘤部位获得CDC。